exRNAdisease

General Information

Database ID:

exR0088191

RNA Name:

hsa-miR-34a-5p

RNA Type:

miRNA

Chromosome:

chr1

Starnd:

Coordinate:

Start Site(bp):

9151735

End Site(bp):

9151756

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
TMEM109	chr11	60914158	60923443	+
RTL8A	chrX	135050932	135052196	-
CD151	chr11	832887	839831	+
PXDC1	chr6	3722614	3752026	-
PTGFRN	chr1	116909916	116990353	+
STK38L	chr12	27243968	27325959	+
CPSF6	chr12	69239569	69274358	+
TNRC6B	chr22	40044817	40335808	+
MTMR9	chr8	11284816	11328146	+
NDST1	chr5	150485818	150558211	+
SEC61A1	chr3	128051641	128071683	+
KMT2D	chr12	49018975	49059774	-
HMGCS1	chr5	43287470	43313512	-
ARPP19	chr15	52547045	52569883	-
CALM3	chr19	46601074	46610782	+
MYCN	chr2	15940550	15947007	+
ZNF623	chr8	143636013	143656418	+
PHF19	chr9	120855651	120894896	-
NFKBIA	chr14	35401511	35404749	-
TKFC	chr11	61333210	61353295	+
NCOA1	chr2	24491914	24770702	+
ZDHHC17	chr12	76763588	76853696	+
PPARD	chr6	35342558	35428191	+
TOB2	chr22	41433494	41446801	-
ATXN2L	chr16	28823035	28837237	+
AGTRAP	chr1	11736084	11754802	+
SMC1A	chrX	53374149	53422728	-
JAG1	chr20	10637684	10673999	-
ACSL1	chr4	184755595	184826818	-
IL2RB	chr22	37125843	37175054	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0001723	chr7	91924202	91948826	+
hsa_circ_0001495	chr5	68470703	68471364	+
hsa_circ_0000943	chr19	47421744	47440665	+
hsa_circ_0000038	chr1	28800065	28802803	+
hsa_circ_0001865	chr9	86292641	86293514	-
hsa_circ_0001146	chr20	34241449	34246936	-
hsa_circ_0001164	chr20	45891031	45923523	-

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC018521.1	chr17	47945424	47981736	+
AC116913.1	chr15	66488658	66492109	-
HCG18	chr6	30286690	30327382	-
KCNQ1OT1	chr11	2608328	2699994	-
LINC00665	chr19	36313067	36331770	-
NEAT1	chr11	65422774	65445540	+
SNHG7	chr9	136721366	136728184	-
TERC	chr3	169764520	169765060	-
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.